These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 14613319)

  • 21. Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.
    Neumeyer JL; Gu XH; van Vliet LA; DeNunzio NJ; Rusovici DE; Cohen DJ; Negus SS; Mello NK; Bidlack JM
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2735-40. PubMed ID: 11591513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Syntheses of novel pyrazolomorphinans and their binding to mu- and kappa-opioid-receptors.
    Stroetmann I; Seitz G; Wanner KT; Höfner G
    Pharmazie; 1998 Feb; 53(2):87-90. PubMed ID: 9540104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel ligands for the opioid receptors: synthesis and structure-activity relationships among 5'-aryl and 5'-heteroaryl 17-cyclopropylmethyl-4,5 alpha-epoxypyrido[2',3':6,7]morphinans.
    Ananthan S; Khare NK; Saini SK; Davis P; Dersch CM; Porreca F; Rothman RB
    Bioorg Med Chem; 2003 Sep; 11(18):4143-54. PubMed ID: 12927876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and opioid receptor activity of indolopropellanes.
    Li F; Gaob L; Yin C; Chen J; Liu J; Xie X; Zhang A
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4603-6. PubMed ID: 19595591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-Substituted 9beta-methyl-5-(3-hydroxyphenyl)morphans are opioid receptor pure antagonists.
    Thomas JB; Zheng X; Mascarella SW; Rothman RB; Dersch CM; Partilla JS; Flippen-Anderson JL; George CF; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 1998 Oct; 41(21):4143-9. PubMed ID: 9767649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities.
    Lattanzi R; Spetea M; Schüllner F; Rief SB; Krassnig R; Negri L; Schmidhammer H
    J Med Chem; 2005 May; 48(9):3372-8. PubMed ID: 15857143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.
    Decker M; Fulton BS; Zhang B; Knapp BI; Bidlack JM; Neumeyer JL
    J Med Chem; 2009 Dec; 52(23):7389-96. PubMed ID: 19634902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.
    Provencher BA; Sromek AW; Li W; Russell S; Chartoff E; Knapp BI; Bidlack JM; Neumeyer JL
    J Med Chem; 2013 Nov; 56(21):8872-8. PubMed ID: 24107104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine.
    Thomas JB; Fall MJ; Cooper JB; Rothman RB; Mascarella SW; Xu H; Partilla JS; Dersch CM; McCullough KB; Cantrell BE; Zimmerman DM; Carroll FI
    J Med Chem; 1998 Dec; 41(26):5188-97. PubMed ID: 9857089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.
    Bennett MA; Murray TF; Aldrich JV
    J Pept Res; 2005 Mar; 65(3):322-32. PubMed ID: 15787962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guanidino N-substituted and N,N-disubstituted derivatives of the kappa-opioid antagonist GNTI.
    Black SL; Chauvignac C; Grundt P; Miller CN; Wood S; Traynor JR; Lewis JW; Husbands SM
    J Med Chem; 2003 Dec; 46(25):5505-11. PubMed ID: 14640558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
    Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
    Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents.
    Ghirmai S; Azar MR; Polgar WE; Berzetei-Gurske I; Cashman JR
    J Med Chem; 2008 Mar; 51(6):1913-24. PubMed ID: 18298057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.
    McLamore S; Ullrich T; Rothman RB; Xu H; Dersch C; Coop A; Davis P; Porreca F; Jacobson AE; Rice KC
    J Med Chem; 2001 Apr; 44(9):1471-4. PubMed ID: 11311071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
    Peng X; Knapp BI; Bidlack JM; Neumeyer JL
    Bioorg Med Chem; 2007 Jun; 15(12):4106-12. PubMed ID: 17433695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and pharmacological characterization of a novel, highly potent, peptidomimetic delta-opioid radioantagonist, [3H]Tyr-Tic-(2S,3R)-beta-MePhe-Phe-OH.
    Birkas E; Kertesz I; Toth G; Bakota L; Gulya K; Szucs M
    Neuropeptides; 2008 Feb; 42(1):57-67. PubMed ID: 18068762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Syntheses of 4,6'-epoxymorphinan derivatives and their pharmacologies.
    Nemoto T; Fujii H; Narita M; Miyoshi K; Nakamura A; Suzuki T; Nagase H
    Bioorg Med Chem; 2008 Apr; 16(8):4304-12. PubMed ID: 18337104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes.
    Lester PA; Traynor JR
    Brain Res; 2006 Feb; 1073-1074():290-6. PubMed ID: 16443205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
    Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
    Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.